NanoString Technologies Inc. Launches Its First Commercial Diagnostic Product in the European Union and Israel

Published: Feb 19, 2013

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced it has launched its first commercial in vitro diagnostic product, the Prosigna™ Breast Cancer Prognostic Gene Signature Assay for the nCounter® diagnostic system in the European Union (EU) and Israel. Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna assay provides a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), and a prognostic score (referred to as the risk of recurrence, or ROR, score). The ROR score estimates the probability of cancer recurrence by 10 years in post-menopausal women with hormone receptor-positive early-stage breast cancer who have been treated with endocrine therapy alone. The Prosigna assay was validated in two clinical studies with more than 2,400 patient samples and results were presented at the 2011 and 2012 San Antonio Breast Cancer Symposium.

Back to news